Layoffs at Pfizer will drive a significant reduction in its workforce this year as the company advances a multiyear cost saving program. The layoffs will affect more than 200 roles and bring staffing down by 2025, according to Bloomberg News.
What changed inside the company’s unit
Pfizer will reduce its headcount from about 300 employees to roughly 70 by the end of 2025. The layoffs follow internal changes made earlier in the month, including a transition in leadership when Rea Lal replaced Sabine Bruckner as country head under a narrower mandate. The shift signals a deeper push to simplify reporting lines and consolidate roles before the next phase of the cost program.
Impact on workforce and sector trends linked to layoffs at Pfizer
The layoffs reflect broader adjustments across global drugmakers responding to weaker post pandemic demand for Covid related products. Analysts noted that updated corporate tax rules have also influenced how multinational pharma companies evaluate their footprints and cost structures. Novartis recently disclosed plans to remove up to 550 jobs as it consolidates operations and expands automation. Sector experts said these changes show how organisations are preparing for slower revenue cycles while increasing investment in fewer but more scalable units. For employees, the transition highlights an industry wide shift toward leaner teams.
How the cost program works
Pfizer aims to achieve US$7 billion in savings by 2027. The company stated that it is “streamlining and realigning” resources to raise efficiency but did not comment on the number of redundancies. A trimmed reporting structure now groups more functions into fewer units, which executives say will help maintain long term competitiveness. Analysts will track whether the layoffs deliver the expected efficiency gains without reducing capabilities that support future growth.
Shares of Pfizer moved to US$25.48 on Wednesday afternoon, up from US$25.33 at the previous close. Investors will watch how the restructuring influences operational goals and overall performance through 2027.
